BBI-DSP7888-101
Total Payments
$158,215
Transactions
24
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $158,215 | 24 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $158,215 | 24 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy (WIZARD201G) | Sumitomo Dainippon Pharma Co., Ltd. | $158,215 | 0 |
Top Doctors Receiving Payments for BBI-DSP7888-101
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Chicago, IL | $158,215 | 24 |
Ad
Manufacturing Companies
- Sumitomo Dainippon Pharma Co., Ltd. $158,215
Product Information
- Type Drug
- Total Payments $158,215
- Total Doctors 0
- Transactions 24
About BBI-DSP7888-101
BBI-DSP7888-101 is a drug associated with $158,215 in payments to 0 healthcare providers, recorded across 24 transactions in the CMS Open Payments database. The primary manufacturer is Sumitomo Dainippon Pharma Co., Ltd..
Payment data is available from 2017 to 2017. In 2017, $158,215 was paid across 24 transactions to 0 doctors.
The most common payment nature for BBI-DSP7888-101 is "Unspecified" ($158,215, 100.0% of total).
BBI-DSP7888-101 is associated with 1 research study, including "A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy (WIZARD201G)" ($158,215).